Deerfield Management BBIO Position
Active10-Fund ConvergenceDeerfield Management held their position in BridgeBio Pharma Inc. (BBIO) in Q4 2025, holding $61.2M worth of shares across 4,885,446 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
BBIO is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 20.2% of float with 7.8 days to cover, indicating significant bearish positioning against Deerfield's long thesis.
About BridgeBio Pharma Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Full company profile →Short Interest
20.2%
7.8 days to cover
Deerfield Management BBIO Position History
Frequently Asked Questions
Does Deerfield Management own BBIO?
Yes. As of Q4 2025, Deerfield Management holds 4,885,446 shares of BridgeBio Pharma Inc. (BBIO) valued at $61.2M. This data comes from their SEC 13F filing.
How many hedge funds own BBIO?
10 specialist biotech hedge funds currently hold BBIO, including Cormorant Asset Management, Driehaus Capital, Deep Track Capital and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy BBIO?
Deerfield Management's position in BBIO was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's BBIO position increasing or decreasing?
Deerfield Management held their BBIO position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BBIOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →